Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.
Aberrant acetylation has been strongly linked to tumorigenesis, and the modulation of acetylation through targeting histone deacetylases (HDACs) is gathering increasing pace as a viable therapeutic strategy. A genome-wide loss-of-function screen identified HR23B, which shuttles ubiquitinated cargo p...
Main Authors: | Fotheringham, S, Epping, M, Stimson, L, Khan, O, Wood, V, Pezzella, F, Bernards, R, La Thangue, N |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
HDAC inhibitor-based therapies and haematological malignancy.
by: Stimson, L, et al.
Published: (2009) -
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
by: Khan, O, et al.
Published: (2010) -
Biomarkers for predicting clinical responses to HDAC inhibitors.
by: Stimson, L, et al.
Published: (2009) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
by: New, M, et al.
Published: (2013) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
by: New, M, et al.
Published: (2013)